Penumbra Inc.
Penumbra Reports Strong Q4 and Full Year 2024 Financial Results
Summary
Penumbra, Inc. announced robust financial results for Q4 and the full year 2024, with significant revenue growth and improved profitability. Adjusted revenue increased by 12.9% in Q4 and 13.4% for the full year, driven by strong sales in the U.S. and a slight decline in international regions. Non-GAAP income from operations and adjusted EBITDA also showed improvement, reflecting operational efficiencies and cost management. The company projected continued growth for 2025 with a target to achieve at least a 100 basis point expansion in gross margin.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement